Allakos Inc , a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO at $18 per share. The Analysts Following the IPO quiet period expiration, Goldman Sachs analyst Terrence Flynn initiated coverage of Allakos with a Neutral rating and $31 price target. William Blair's Tim Lugo initiated coverage of Allakos with an Outperform rating and $72 fair value estimate. Source